BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Germany's BioNTech says it needs only six weeks to create a coronavirus vaccine targeting the mutated virus rampaging across the U.K. But BioNTech stock crumbled Tuesday, despite the news. The post BioNTech CEO: It's Highly Likely Covid Vaccine Will Work On U.K. Strain appeared first on Investor's Business Daily.

BioNTech CEO: It's Highly Likely Covid Vaccine Will Work On U.K. Strain

Moderna

Pfizer

Even with the relief brought by the conditional approval of two coronavirus vaccines, a more virulent and contagious variant of the virus in the U.K. has emerged.  Pfizer Inc. (NYSE: PFE), with its German partner BioNTech SE – ADR (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) are the two companies that have received approval for emergency use of their respective investigational vaccines.

Moderna, Pfizer Testing Coronavirus Vaccine Against New Strain

Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine candidate is the first COVID-19 vaccine to be granted conditional authorization in Europe.

Pfizer/BioNTech COVID-19 Vaccine Gets Authorization in Europe

BioNTech's CEO said on Tuesday that while it is currently unclear whether the vaccine can protect against the new U.K. strain, it is “highly likely” the shot can protect against new variants.

Pfizer-BioNTech, Moderna Test Vaccines Against New Covid-19 Variant Spreading Across U.K.

It might seem like it, based on the stock's recent performance.

Is Pfizer's COVID Vaccine Growth Story Already Over?

The Pfizer-BioNTech vaccine has landed in the tiny-island nation after it was approved for distribution last week.

Singapore is first Asian country to receive batch of Pfizer's Covid-19 vaccine

Ugur Sahin, CEO of BioNTech SE (NASDAQ: BNTX) — the German partner of Pfizer Inc (NYSE: PFE) — expressed confidence that two companies' jointly-developed vaccine is effective against a new mutation of COVID-19, Reuters reported Monday.  What Happened: Sahin told Germany's Bild TV that BioNTech would look into the mutation that has emerged out of the United Kingdom in the coming days and viewed the matter “with a degree of soberness,” as per Reuters.

Pfizer Partner BioNTech Confident Vaccine Effective Against UK Mutant COVID-19 Strain

BNT162b2 gets another green light from a top healthcare regulator.

Pfizer and BioNTech's Coronavirus Vaccine Approved in Europe

The U.S. is planning a study to find out why some people have suffered from allergic reactions after receiving a Covid vaccine, an NIAID official told CNBC.

U.S. plans to study allergic reactions from Pfizer's Covid vaccine

Shares of Pfizer Inc. were down 1.1% and BioNTech SE shares were up 1.2% in trading on Monday after the companies said their COVID-19 vaccine has been recommended for authorization in the European Union. The Committee for Medicinal Products for Human Use made the recommendation, and the European Commission is expected to review it and make a final decision in the "near future.

E.U. committee recommends authorization of BioNTech and Pfizer's coronavirus vaccine

Mainz, Germany, December 21, 2020 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will hold a press conference including a video webcast on Tuesday, December 22, 2020, to provide an update on the status of the COVID-19 vaccine development program of its lead vaccine candidate BNT162b2. The event will be held virtual and in English:

BioNTech to Hold Press Conference to Provide an Update on COVID-19 Vaccine Development Program

The European Commission gave approval on Monday for the use of the COVID-19 vaccine jointly developed by U.S. company Pfizer and its German partner BioNTech, the final step to allowing Europe to start inoculations within a week.

European Commission gives final approval to Pfizer/BioNTech vaccine

EMA's move paves way for inoculations to begin across Europe within next few days

Pfizer/BioNTech Covid vaccine approved by European regulator

Pfizer Inc. (NYSE: PFE)-BioNTech SE's – ADR (NASDAQ: BNTX) coronavirus vaccine candidate – BNT162b2 – is inching closer to getting conditional approval in European Union, after similar approvals in the U.S., U.K., Bahrain Saudi Arabia, Canada, Mexico and Switzerland. What Happened: Following a rigorous evaluation of BNT162b2, which is to go by the trade name Comirnaty in Europe, the European Medicines Agency's Committee For Medicinal Products For Human Use concluded by consensus that sufficiently robust data on the safety and efficacy of the vaccine are now available to recommend a formal conditional marketing authorization.

EMA Committee Recommends Conditional Approval Of Pfizer-BioNTech Vaccine In Europe

The European Union has authorized its first vaccine against Covid-19, joining the U.S. and the U.K. in allowing the shots developed by Pfizer and BioNTech.

European Union Approves Pfizer-BioNTech Covid Vaccine

The European Union has so far managed to secure 2 billion doses of various Covid-19 vaccines.

EU Drug Regulator Approves Pfizer-BioNTech Covid-19 Vaccine For Emergency Use

Here's what you need to know about the impact of Covid-19 to navigate the markets today.

European Regulators Clear Pfizer's Covid-19 Vaccine

Europe's medicines regulator on Monday approved the use of the COVID-19 vaccine jointly developed by U.S. company Pfizer and its German partner BioNTech, putting Europe on course to start inoculations within a week.

Regulator clears way for use of Pfizer COVID-19 vaccine in Europe

The European Commission should give its decision by Monday evening on the COVID-19 vaccine developed by Pfizer and BioNTech, which should pave the wave for vaccinations to begin across the 27 EU countries this year.

EU to decide on Pfizer/BioNTech COVID-19 vaccine by evening, EU chief

The European drug regulator said on Monday the use of the COVID-19 vaccine jointly developed by U.S. company Pfizer and its German partner BioNTech on pregnant women should be done on a case by case basis.

EU drug regulator: Pfizer-BioNTech vaccine should be on case by case for pregnant women

The European Union drug regulator recommended the EU authorize the Pfizer and BioNtech COVID-19 vaccine on Monday. Experts on the European Medicines Agency's human medicines committee concluded the Pfizer vaccine was safe and effective for people 16-years-old and older using available data. The decision will lead the way for a EU-wide authorization of the vaccine.

European Medicines Agency just recommended the Pfizer and BioNtech COVID-19 vaccine for use in EU

The European Medicines Agency said it had recommended granting conditional marketing authorization for the vaccine in people aged 16 and over.

European Medicines Agency authorizes Pfizer vaccine for use in the EU

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion to recommend the conditional marketing authorization (CMA) of the Pfizer-BioNTech COVID-19 Vaccine (also known as BNT162b2), for active immunization to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 16 years of age and older. The purpose of a

Pfizer and BioNTech Receive CHMP Positive Opinion for their COVID-19 Vaccine

A week into the COVID-19 mass vaccination efforts, the U.S. Centers For Disease Control and Prevention reports that — of the 2,838,225 doses distributed around the country — over 556,208 doses had been administered as of Sunday. What Happened: The U.S. Food and Drug Administration has approved two vaccine candidates so far.

CDC Says Over 556,208 Pfizer/BioNTech COVID-19 Shots Administered In Week 1 Of Inoculation Drive

AbbVie

ADC Therapeutics

Allogene Therapeutics Inc

Legend Biotech

Y-Mabs Therapeutics Inc

Overland Pharmaceuticals will form a $117 million China JV with Allogene Therapeutics to bring allogenic CAR-T drugs to China. Harbour BioMed has out-licensed its fully human SARS-CoV-2 neutralizing antibody, 47D11, to AbbVie.

News for BioNTech SE Stock (BNTX)